NEWS & PRESS
Solarea Bio Investigators Receive National Academy of Medicine Healthy Longevity 2022 Quickfire Challenge Award
Work focuses on studying the mycobiome as a novel class of probiotics for the dietary management of inflammation associated with aging
Sep 29 2022
Solarea Bio Announces Licensing Agreement with ADM
Solarea Bio, a biotech company based in Cambridge, MA that is developing microbial-based solutions to aid human health, today announced it has signed a technology licensing agreement with global nutrition leader ADM
Oct 19 2021
Juliana Soto Named To Georgia Tech Alumni’s 40 Under 40 List
In the U.S., about 10 million Americans are currently living with osteoporosis or osteopenia and the majority are women. For Maria Soto-Giron, that statistic is personal. Her motivation for working in biotech looking for treatments to reduce chronic inflammation is her mother who has rheumatoid arthritis and osteoporosis.
Jul 15 2020
Eric Schott’s Ph.D. work covered by Forbes.
While your body is home to millions of different types of bacteria, it turns out that some may be more welcome than others.
But now we have more reason to believe that specific bacteria living in the gut microbiome may, in fact, be responsible for a common debilitating disease.
Apr 23 2018
Illumina Accelerator Sees ‘Huge Impact in Genomics’ in New Startups
—Solarea Bio: The only company not from the Bay Area, Boston-based Solarea is developing probiotic treatments that are derived from natural sources, Cashin says.
Jul 26 2017